Skip to content

H.R. 1476 · 119th Congress (2025–2027)

PLASMA Act

This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.

Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).

The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.

Show official title

To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 1476’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Richard Hudson (R-NC-9)
Cosponsors
5 cosponsors

3 original · 2 later

  1. Rep. Donald G. Davis (D-NC-1)· Original · Feb 21, 2025
  2. Rep. Gregory F. Murphy (R-NC-3)· Original · Feb 21, 2025
  3. Rep. Scott H. Peters (D-CA-50)· Original · Feb 21, 2025
  4. Rep. David Rouzer (R-NC-7)· Later · May 5, 2025
  5. Rep. Brad Knott (R-NC-13)· Later · Jun 3, 2025
Policy area
Health
Subjects
  • Blood and blood diseases
  • Drug therapy
  • Health care costs and insurance
  • Manufacturing
  • Medicare
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Feb 21, 2025
  2. HouseWays and MeansReferred Feb 21, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. PLASMA Act

    Display title, Short title · Introduced in House

  2. Preserving Life-saving Access to Specialty Medicines in America Act

    Short title · Introduced in House

  3. To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.

    Official title · Introduced in House